+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Glioblastoma Drug"

From
From
Glioblastoma Multiforme (GBM) Treatment Market Report 2025 - Product Thumbnail Image

Glioblastoma Multiforme (GBM) Treatment Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Glioblastoma - Pipeline Insight, 2024 - Product Thumbnail Image

Glioblastoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 440 Pages
  • Global
From
Glioblastoma multiforme (GBM) - Pipeline Insight, 2024 - Product Thumbnail Image

Glioblastoma multiforme (GBM) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market 2024-2028 - Product Thumbnail Image

Glioblastoma Multiforme Treatment Market 2024-2028

  • Report
  • October 2024
  • 137 Pages
  • Global
From
From
From
Recurrent Glioblastoma - Pipeline Insight, 2024 - Product Thumbnail Image

Recurrent Glioblastoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 200 Pages
  • Global
From
From
From
From
From
From
From
Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Loading Indicator

The Glioblastoma Drug market is a subset of the larger Brain Cancer Drug market. It is composed of drugs used to treat glioblastoma, a type of brain cancer. These drugs are typically used in combination with surgery, radiation, and chemotherapy to treat the disease. Common drugs used to treat glioblastoma include temozolomide, bevacizumab, and lomustine. These drugs are used to reduce tumor size, slow tumor growth, and reduce symptoms. The Glioblastoma Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Merck, Roche, Pfizer, and Bristol-Myers Squibb. Other companies in the market include Celgene, AstraZeneca, and Eli Lilly. Show Less Read more